The U.K. agency responsible for evaluating the cost-effectiveness of drugs has advised against using Biogen's Spinraza to treat a rare disorder known as spinal muscular atrophy (SMA).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,